14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRESY vs HHS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRESY carries a Unified Composite Score of 54.6/100 (HOLD) at $9.17 (56.6x Forward P/E, 19.3% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin).
Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY).
Technical & Structure Timing Caution: CRESY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6); meanwhile HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRESY vs HHS. Trailing 12-month operating profitability (CRESY 19.3% vs HHS -3.2%) and valuation multiples (CRESY 56.6x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $29.9M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment19.3% of Rev ($30M)
90D Engineering Disclosures0 Published
Investor FAQ CRESY vs HHS Key Questions & Quantitative Answers
As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRESY carries a Unified Composite Score of 54.6/100 (HOLD) at $9.17 (56.6x Forward P/E, 19.3% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY). Technical & Structure Timing Caution: CRESY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6); meanwhile HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRESY leads the Growth & Scale pillar: CRESY posts +20.4% YoY revenue growth and -93.6% YoY earnings growth on $1.15B TTM revenue (42.1% gross margin, 19.3% operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, CRESY generates $1.15B in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, CRESY deploys 22.8% of Rev ($262M) (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.
HHS screens cheaper on headline valuation multiples. CRESY trades at 56.6x Forward P/E, 6.3x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (20.6% EBITDA margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRESY (8.6% ROE) versus HHS (-30.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CRESY carries 74.0% implied volatility (100th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.82β · 59% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.